There’s a New Link Between Gut Health and Alzheimer’s Disease

For years, scientists have known that the gut microbiome of people with Alzheimer’s differs from that of healthy people. What remains unclear is whether these differences are a consequence of the disease, contribute to it, or simply accompany it. It is possible that part of the puzzle lies not in the gut bacteria themselves but in the molecules they produce, which end up circulating throughout the body.

A team of scientists believes it has found one such molecule. In a study published in Nature Communications , the researchers identified imidazole propionate (ImP)—a compound produced by certain gut bacteria—as a possible link between the microbiome and Alzheimer’s disease.

The hypothesis put forward by the researchers begins in the gut. Some bacteria use an amino acid called histidine, and by metabolizing it, produce ImP. Some of this molecule can enter the bloodstream and circulate throughout the body.

The problem begins at the brain’s border. Experiments in the new study indicate that ImP can weaken the blood-brain barrier, which protects the brain and controls what substances can pass into it via blood . A less effective barrier can help the metabolite enter the brain, where researchers found that it can interact directly with neurons.

This is where two key players in Alzheimer’s disease come into play: the amyloid beta and tau proteins. In a brain affected by Alzheimer’s, amyloid beta accumulates, forming plaques between neurons. Tau, for its part, undergoes abnormal changes that alter its function and promote the formation of harmful structures within cells. Both phenomena are closely linked to neuronal deterioration and constitute two of the disease’s main biological hallmarks.

In the experiments, ImP appears to have the ability to exacerbate both. The researchers found that it can promote the accumulation of amyloid beta plaques and increase tau modification through a process known as phosphorylation.

The model presented in the study functions as a chain: Certain gut bacteria produce ImP; the metabolite enters the bloodstream; it can compromise the blood-brain barrier and reach the brain; and, once there, it promotes changes related to amyloid beta and tau.

But just because a biological explanation is coherent doesn’t mean that the entire chain is actually occurring in the human body. To test the extent of this relationship, the researchers first looked for evidence of it in humans and then tested different parts of the mechanism in mice and cells.

The scientists analyzed ImP levels in the blood of 1,196 cognitively healthy adults with a mean age of 61.2 years. Those with higher levels of the metabolite scored, on average, worse on cognitive tests. They also had higher levels of pTau-217—a modified form of the tau protein used as a biomarker for Alzheimer’s—and of NfL, a protein released in greater quantities when neurons are damaged. Both can be measured in the blood and provide clues to changes in the brain even before symptoms appear.